Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Day One Biopharmaceuticals, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04775485CT.gov A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Low Grade Glioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tovorafenib (this asset) | Day One Biopharmaceuticals, Inc. | P2 | CC · 43 |
| Irinotecan | Beijing Sanbo Brain Hospital | P2 | BB |
| FET | Thomas Hope | P2 | B |
| Tazemetostat | National Cancer Institute (NCI) | P2 | B |
| Olaparib | National Cancer Institute (NCI) | P2 | B |
| Binimetinib | National Cancer Center, Japan | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Carboplatin | Julie Krystal | P1/2 | CCC |
| Mebendazole | Julie Krystal | P1/2 | CCC |
+6 more in the Low Grade Glioma cohort
Other indications for Tovorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pilocytic Astrocytoma | — | P2 | CC · 47 |
| Melanoma | — | P2 | CC · 44 |
| Non-Small Cell Lung Carcinoma | — | P2 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tovorafenib in Low Grade Glioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tovorafenib-low-grade-glioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →